Synonyms: 3'-keto-Bmt(1)-Val(2)-cyclosporin A | Amdray® | PSC-833 | PSC833 | SDZ PSC 833 | SDZ PSC833 | SDZ-PSC-833
Compound class:
Peptide
Comment: Valspodar is a cyclosporin analogue. It inhibits the multidrug resistance efflux pump/transporter, p-glycoprotein (ABCB1) and via this mechanism can reverse cancer cell resistance to chemotherapeutics in cancers that overexpress ABCB1 [1]. Valspodar does not induce the immunosuppressive effects of cyclosporin A.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Valspodar was evaluated in clinical trials to determine its ability to enhance cancer cell sensitivity to chemotherapy drugs. Development was terminated at Phase 3. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00002878 | Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 3 Interventional | Eastern Cooperative Oncology Group | ||
NCT00002937 | Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer | Phase 2 Interventional | City of Hope Medical Center | ||
NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | Phase 3 Interventional | National Cancer Institute (NCI) |